# 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression

> **NCT02363738** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 60 (actual)

## Conditions studied

- Bipolar Depression

## Interventions

- **DRUG:** Infliximab
- **OTHER:** Saline

## Key facts

- **NCT ID:** NCT02363738
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2017-04
- **Final completion:** 2017-04
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-07-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02363738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02363738, "12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02363738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*